Blonanserin

CHEMBL178803 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

367.5 g/mol

LogP

5.5

Phase

4

An atypical antipsychotic used primarily in Japan and some other Asian countries to treat schizophrenia. It blocks dopamine D2 and D3 receptors as well as serotonin 5-HT2A receptors to reduce psychotic symptoms such as hallucinations and delusions. It has a lower tendency to cause certain metabolic side effects compared to some other antipsychotics.

Masse moléculaire

367,5000 g/mol

LogP

5,50

TPSA

19,40 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Schizophrenia

Mécanisme d'action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1

InChI

InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3

Molecular Formula

C23H30FN3

HBD / HBA

- / 4

Liaisons Rotatives

3

Atomes Lourds

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An atypical antipsychotic used primarily in Japan and some other Asian countries to treat schizophrenia. It blocks dopamine D2 and D3 receptors as well as serotonin 5-HT2A receptors to reduce psychotic symptoms such as hallucinations and delusions. It has a lower tendency to cause certain metabolic side effects compared to some other antipsychotics.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Blonanserin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL178803. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 125564. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Blonanserin sur PillFYI

Structure

Données Clés

Formule: C23H30FN3

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.